A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)
Macular Edema Secondary to Retinal Vein Occlusion
About this trial
This is an interventional treatment trial for Macular Edema Secondary to Retinal Vein Occlusion
Eligibility Criteria
Inclusion Criteria: Adult ≥18 years of age (or country's legal age of adulthood if the legal age is >18 years) at the time of signing the informed consent. Treatment-naïve macular edema involving the foveal center secondary to RVO (BRVO, HRVO, or CRVO) diagnosed within 16 weeks (112 days) before the screening visit in the study eye. Early Treatment Diabetic Retinopathy Study BCVA letter score of 73 to 24 (20/40 to 20/320) at screening and baseline visits in the study eye. Decrease in BCVA determined to be primarily the result of RVO in the study eye. Mean CST ≥300 μm on optical coherence tomography (OCT) if excluding Bruch's membrane (e.g., Cirrus or Topcon) or ≥320 μm if including Bruch's membrane (e.g., Heidelberg Spectralis), confirmed by the reading center at the screening visit and by the site at baseline visit in the study eye. Capable of giving signed informed consent form (ICF) by study participant or legally acceptable representative, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. US participants will be required to have a Health Insurance Portability and Accountability Act (HIPAA) authorization; in other countries, as applicable according to national laws. Women of childbearing potential (WOCBP) or men who are sexually active with partners of childbearing potential must agree to use highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last administration of study intervention. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for participation in clinical studies and fulfil the conditions set on Section 10.4.2. Exclusion Criteria: Concurrent disease that causes substantial decrease of BCVA, is expected to limit BCVA recovery or is likely to require medical or surgical intervention during the study in the study eye. Presence or history of the following ocular conditions: Advanced age-related macular degeneration (neovascular AMD or geographic atrophy) in the study eye. Diabetic macular edema or diabetic retinopathy, defined in diabetic participants as diabetic retinopathy lesions outside the area of the vein occlusion in the study eye and anywhere in the retina in the fellow eye. Anterior segment neovascularization, vitreous hemorrhage, retinal detachment in the study eye. Vitreomacular traction, epiretinal membrane or structural damage to the macula that is considered by the Investigator to significantly affect central vision or preclude improvement in vision in the study eye. Macular hole of stage 2 and above in the study eye. Myopia of a spherical equivalent of at least 8 diopters prior to any refractive or cataract surgery in the study eye. Corneal transplant or corneal dystrophy in the study eye. Idiopathic or autoimmune uveitis in the study or in the fellow eye. Presence of the following ocular conditions at screening or baseline visit: Significant media opacities, including cataract, that interfere with BCVA, or imaging assessments (e.g., fundus photography [FP], OCT) in the study eye. Aphakia, or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium-aluminum-garnet [YAG] posterior capsulotomy performed more than 30 days before the screening visit), in the study eye. Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication); or history or likely future need of glaucoma surgery in the study eye. Intraocular inflammation/infection (including trace, or above, cells in the anterior chamber and/or vitreous) within 12 weeks (84 days) of the screening visit in the study or in the fellow eye. Extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in the study or in the fellow eye. Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg) at the screening visit or baseline visit. Uncontrolled diabetes mellitus, defined by hemoglobin A1c (HbA1c) >12% at the screening visit. History of cerebrovascular accident or myocardial infarction within 24 weeks (168 days) before the screening visit or between screening and baseline visits. Renal failure requiring dialysis, or renal transplant at screening or potentially during the study. Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti-VEGF or other agent) or surgery for RVO in the study eye. Previous administration of systemic anti-angiogenic medications for any condition. Prior treatment of the study eye with any of the following drugs (any route of ophthalmic administration) or procedures: Anti-angiogenic drugs at any time including investigational therapy (e.g., with anti-angiopoietin/anti-VEGF bispecific monoclonal antibodies). Previous use topical steroids within 4 weeks (28 days) from the screening visit, or intraocular or periocular steroids within 16 weeks (112 days) from the screening visit, or steroid implants at any time. Previous treatment with intraocular or periocular implant, gene therapy, or cell therapy at any time. Treatment with ocriplasmin at any time. Vitreoretinal surgery (including scleral buckling) at any time. Any intraocular surgery, including cataract surgery, within 12 weeks (84 days) before the screening visit. Previous treatment with retinal laser photocoagulation. Prior treatment of the fellow eye with any of the following: a. Gene therapy, or cell therapy in the fellow eye at any time. Participation in other clinical studies requiring administration of investigational treatments (other than vitamins and minerals) at the time of screening visit, or within 30 days or 5 half-lives of administration of the previous study intervention, whichever is longer.
Sites / Locations
- Retina Consultants of Orange County
- Mountain View | Ophthalmology
- South Coast Retina Center
- Northern California Retina-Vitreous Associates
- Southern California Desert Retina Consultants
- California Eye Specialists
- Southern California Permanente Medical Group
- Stanford University
- Retina Consultants of Southern Colorado, PC
- New England Retina Associates
- Rand Eye InstituteRecruiting
- National Ophthalmic Research Institute
- Eye Institute of West Florida
- Florida Eye Associates
- Florida Retina Institute
- Retina Specialists
- Fort Lauderdale Eye Institute
- Retina Vitreous Associates of Florida - Saint Petersburg
- East Florida Eye Institute
- University of South Florida
- Center for Retina and Macular Disease
- Marietta Eye Clinic
- Retina Associates IL
- University Retina and Macula Associates
- Retina Associates, LLC
- Retina Care Center
- Cumberland Valley Retina Consultants, PC
- Mid Atlantic Retina Specialists
- Vitreo-Retinal Associates, PC
- Retina Consultants of Minnesota
- Retina Consultants of Nevada
- Sierra Eye Associates
- Retina Center of New Jersey
- NJ Retina
- NJ Retina | Teaneck
- Eye Associates of New Mexico
- Long Island Vitreoretinal Consultants
- Long Island Vitreoretinal Consultants
- Ophthalmic Consultants of Long Island
- Retina Associates of Western New York
- Ophthalmic Consultants of the Capital Region
- University of NC at Chapel Hill (UNC) Ophthalmology
- Wake Forest Baptist Health
- Cincinnati Eye Institute
- Midwest Retina - Main Office
- Retina Consultants, LLC
- Mid Atlantic Retina
- University of Pennsylvania
- Retina Consultants of Charleston
- Palmetto Retina Center, LLC - Florence
- Palmetto Retina Center, LLC
- Charles Retina Institute
- Austin Retina Associates
- Retinal Consultants of Texas - Bellaire
- Texas Retina Associates
- Medical Center Ophthalmology Associates
- Retinal Consultants of Texas - San Antonio
- Rocky Mountain Retina Consultant
- The Retina Group of Washington | Fairfax
- Spokane Eye Clinical Research
- University of Wisconsin - Madison
- Eyeclinic Albury Wodonga
- Marsden Eye Surgery Center
- Strathfield Retina Clinic
- Sydney Eye Hospital
- Sydney Retina Clinic
- Sydney West Retina Pty Ltd
- Adelaide Eye and Retina Centre
- Hobart Eye Surgeons
- Centre for Eye Research
- Lions Eye Institute
- Klinikum Klagenfurt am Wörthersee
- Konventhospital Barmherzige Brüder Linz
- Medizinische Universität Graz
- Kepler Universitätsklinikum Campus III
- Universitätsklinikum AKH Wien
- Hanusch-Krankenhaus Wien
- SEHAT Pentagram
- UMHAT Alexandrovska EAD
- Multiprofile Hospital for Active Treatment Sveta Sofia
- Specialized Hospital For Active Treatment of Eye Diseases Zora
- Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna
- The Second Hospital of Anhui medical university
- Guangzhou Aier Eye Hospital
- Shijiazhuang General Hospital
- Hebei Eye Hospital
- Henan Provincial Ophthalmology Hospital (Henan Eye Institute
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
- Renmin Hospital of Wuhan University
- The First People's Hospital of Xuzhou
- Eye Center of the second Bethune Hospital, jinlin University
- Shenyang Fourth People's Hospital - Ophthalmology
- Aier Eye Hospital(SHENYANG)
- The People's Hospital of Ningxia Hui Autonomous Region
- Shanxi Provincial Eye Hospital
- The First Affiliated Hospital of Xi'an Jiaotong University
- Qilu Hospital of Shandong University
- West China Hospital,Sichuan University
- Aier Eye Hospital (Chengdu)
- ZheJiang Provincial People's Hospital
- Dongyang People's Hospital
- The Affiliated Eye Hospital of Wenzhou Medical College
- Beijing Aier Intech Eye Hospital Co. LTD - Ophthalmology
- China-Japan Friendship Hospital
- Beijing Hospital
- Capital Medical University (CMU) - Beijing Tongren Hospital
- Peking Union Medical College Hospital CAMS
- Peking University First Hospital
- Chongqing Aier Ophthalmology Hospital
- The First Affiliated Hospital of Chongqing Medical Universit
- Second Hospital Affiliated of Chongqing Medical University
- Zhejiang University School of Medicine - The First Affiliated Hospital - Kidney Disease Center
- Lanzhou University - The Second Hospital (The Second Clinical Medical College of Lanzhou University)
- Eye & Ent Hospital of Fudan University
- China Medical University (CMU) - First Affiliated Hospital
- Tianjin Medical University General Hospital
- Tianjin Medical University Eye Hospital
- TianJin eye hospital
- Fakultni Nemocnice Hradec Kralove
- Fakultni nemocnice Ostrava
- Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice
- FN Kralovske Vinohrady
- Vseobecna fakultni nemocnice v Praze
- Lexum a.s., Evropska ocni klinika
- AXON Clinical s.r.o.
- East Tallinn Central Hospital
- Turman Eye Clinic
- Dr. Kai Noor Silmakabinet OU
- Tartu University Hospital
- Centre Hospitalier National d'Ophthalmologie Quinze-Vingt
- Clinique Rétine Tourny
- CHU Bordeaux - Hopital Pellegrin - Ophtalmologie
- Hôpital Intercommunal - Créteil Cedex
- Hôpital François Mitterrand - Dijon
- Hôpital de la Croix Rousse
- Centre d'Ophtalmologie - Paradis-Monticelli
- Clinique Jules Verne - Nantes
- Centre d'ophtalmologie de l'Odéon
- Hôpital Lariboisière - Paris
- Centre Ophthalmologie d'Imagerie et de Laser
- CM Wolff
- Centre Ophtalmologique Transparence - Tours
- LTD "IQ Clinic"
- LTD Israeli-Georgian Medical Research Clinic "Helsicore"
- LTD "Chichua Medical Center MZERA"
- Caucasus Medical Center- Opthamology
- Universitätsklinikum Freiburg
- Knappschaftskrankenhaus Sulzbach
- Uniklinik Bonn / Eye Clinic
- Universitätsklinikum Düsseldorf / Ophthalmology
- Universitätsmedizin Göttingen - Ophthalmology
- Medizinische Hochschule Hannover (MHH) - University Clinic for Ophthalmology
- Uni Heidelberg / Augenklinik
- Universitaetsklinikum Jena - Ophthalmology
- Klinikum d. Stadt Ludwigshafen - Ophthalmology
- Universitätsklinik Gießen und Marburg GmbH (UKGM) - Ophthalmology
- St. Franziskus-Hospital Münster - Eye Center
- Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum - Eye Clinic and Polyclinic
- Universitaetsklinikum Tuebingen - Ophthalmology
- Budapesti Jahn Ferenc Del-pesti Korhaz es Rendelointezet
- Magyar Honvedseg Egeszsegugyi Kozpont
- University of Semmelweis/ Semmelweis Egyetem
- Bajcsy Zsilinszky Korhaz-Rendelointezet
- Budapest Retina Associates
- Debreceni Egyetem Klinikai Kozpont
- Ganglion Medical Center
- SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont
- Soroka University Medical Center
- Rambam Health Corporation
- Lady Davis Carmel Medical Center
- Edith Wolfson Medical Center
- Hadassah Hebrew University Hospital Ein Kerem
- Meir Medical Center
- Clalit Health Services Rabin Medical Center-Beilinson Campus
- Kaplan Medical Center
- Tel-Aviv Sourasky Medical Center
- Assuta Medical Centers - HaShalom
- Shamir Medical Center (Assaf Harofeh)
- Fondazione PTV Policlinico Tor Vergata
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- IRCCS Fondazione G.B. Bietti Studio e Ricerca in Otalmologia
- Ospedale San Raffaele s.r.l.
- ASST Fatebenefratelli Sacco
- A.O.U. Ospedali Riuniti "Umberto I - G.M.Lancisi - G.Salesi"
- A.O. Ordine Mauriziano
- A.O.U. Consorziale Policlinico
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Nagoya City University Hospital
- International University of Health & Welfare Narita Hospital
- Toho University Sakura Medical Center
- University of Fukui Hospital
- Kurume University Hospital
- Southern Tohoku Eye Clinic
- Gunma University Hospital
- Hyogo Prefectural Amagasaki General Medical Center
- Kobe University Hospital
- Hyogo Medical University Hospital
- Kozawa Eye Hospital and Diabetes Center
- Matsumoto Eye Clinic
- Kagawa University Hospital
- Medical corporation Eiwakai Dannoue Ophthalmology clinic
- Yokohama City University Medical Center
- Mie University Hospital
- Shinshu University Hospital
- National Defense Medical College Hospital
- Shiga University of Medical Science Hospital
- Shida Eye Clinic
- The University of Tokyo Hospital
- Nihon University Hospital
- Chofu Eye Clinic
- Tokyo Medical University Hachioji Medical Center
- Tokyo Metropolitan Institute for Geriatrics and Gerontology
- Tokiwadai Muranaka Eye Clinic
- National Hospital Organization Tokyo Medical Center
- Keio University Hospital
- Tokyo Women's Medical University Hospital
- Yamaguchi University Hospital
- University of Yamanashi Hospital
- Akita University Hospital
- Hayashi Eye Hospital
- Murakami Karindoh Hospital
- Fukushima Medical University Hospital
- Kagoshima University Hospital
- University of Miyazaki Hospital
- Japanese Red Cross Nagasaki Genbaku Hospital
- Osaka Metropolitan University Hospital
- Japanese Red Cross Saitama Hospital
- Japanese Red Cross Wakayama Medical center
- Yamagata University Hospital
- Seoul National University Bundang Hospital
- Gangnam Severance Hospital, Yonsei University Health System
- Pusan National University Hospital
- Yeungnam University Medical Center
- Korea University Ansan Hospital
- Severance Hospital, Yonsei University Health System
- Asan Medical Center
- Seoul National University Hospital
- Samsung Medical Center
- Kim's Eye Hospital
- St. Mary Hospital
- Department of Ophthalmology
- Riga East Clinical University Hospital "Gailezers"
- Latvian American Eye Center
- Hospital of LT University of Health Sciences Kaunas Clinics
- Vilnius University Hospital Santaros Klinikos
- Hospital Al-Sultan Abdullah, UiTM | Opthalmology
- OasisEye Specialists
- Hospital Shah Alam | Ophthalmology
- Hospital Selayang
- Fundacion Hospital Nuestra Señora de la Luz
- Santa Lucia Clinica | Oftalmologica
- FAP Conde de Valenciana, IAP | Oftalmología
- Hospital Angeles Mocel | Oftalmologia
- Instituto Mexicano de Oftalmologia, IMO
- Instituto de la Retina del Bajío SC
- Prywatna Klinika Okulistyczna OFTALMIKA
- Specjalistyczny Osrodek Okulistyczny Oculomedica
- NZOZ Poradnia Okulistyczna Dobry Wzrok
- Profesorskie Centrum Okulistyki
- Gabinet Okulistyczny Prof. Edward Wylegala
- Centrum Medyczne Dietla 19 Sp. z o.o.
- Centrum Medyczne PROMED
- Centrum Diagnostyki i Mikrochirurgii Oka Lens
- Osrodek Chirurgii Oka prof. Zagorskiego Sp. z o.o.
- Centrum Medyczne Piasta 47
- Centro Hospitalar Vila Nova de Gaia/Espinho | Unit 1 - Clinical Research Office
- AIBILI
- Espaco Medico de Coimbra
- CHLC - Hospital dos Capuchos - Servico de Oftalmologia
- Centro Hospitalar Universitario do Porto
- CHUSJ - Hospital Sao Joao
- Clinical Center of Serbia
- Clinical hospital center Zvezdara
- Klinicki centar Vojvodine
- Fakultna Nemocnica s poliklinikou F.D.Roosevelta
- Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
- Univerzitna nemocnica Bratislava, Petrzalka
- Fakultna nemocnica Nitra
- Nemocnica Poprad, a.s.
- Fakultna nemocnica Trencin
- Specialized hospital for ophthalmology OPHTAL
- Instituto Oftalmológico Francisco Gomez Ulla
- Hospital General de Catalunya
- Hospital Universitario Clinica Puerta de Hierro
- Hospital Vall d'Hebron - Servei d'Oftalmologia
- Hospital Clínic i Provincial de Barcelona
- Hospital de la Santa Creu i Sant Pau | Gynecology Department
- Hospital Reina Sofía
- Clínica Universidad de Navarra CUN
- Hospital General Universitario de Valencia
- Hospital del Rio Hortega
- Hospital Miguel Servet
- RétinElysée
- Inselspital Universitätsspital Bern
- Berner Augenklinik am Lindenhofspital
- Vista Klinik
- University Eye Hospital Jules Gonin
- Chiangmai University
- Srinagarind Hospital
- Thammasat University
- Cukurova Universitesi Tip Fakultesi Hastanesi
- SBU Gulhane Egitim ve Arastirma Hastanesi
- Hacettepe Universitesi Tip Fakultesi
- Ankara Etlik City Hospital | Ophthalmology
- Baskent Universitesi Tip Fakultesi Hastanesi
- Gazi Universitesi Tip Fakultesi
- Ankara Numune Egitim ve Arastirma Hastanesi
- Ankara Universitesi Tip Fakultesi Hastanesi
- Ankara Bilkent Sehir Hastanesi
- Adnan Menderes Universitesi Tip fakultesi
- Istanbul Universitesi Istanbul Tip Fakultesi
- Beyoglu Eye Training and Research Hospital
- Ege Universitesi Tip Fakultesi
- Kocaeli Universitesi Tip Fakultesi
- Colchester General Hospital
- Barnet General Hospital
- Leicester Royal Infirmary
- James Paget Hospital
- Epsom General Hospital
- Frimley Park Hospital NHS
- Sunderland Eye Infirmary
- University Hospitals Coventry and Warwickshire NHS Trust
- New Cross Hospital
- St James' University Hospital
- Hull and East Yorkshire Eye Hospital Hull and East Yorkshire
- Bradford Royal Infirmary
- Royal Liverpool University Hospital
- Moorfields Eye Hospital
- York Teaching Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Higher Dose Regimen 1
Higher Dose Regimen 2
Standard of care
Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
Aflibercept 2 mg is administered by standard treatment intervals, followed by adjustment of treatment intervals according to treatment response.